Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats

Xenobiotica

Volumn 42, Issue 4, 2012, Pages 372-388

  Jung, Donald ^a   Jiao, Hailong ^a   Duan, Jian Xi ^a   Matteucci, Mark ^a   Wang, Ronghua ^b  

^a Threshold Pharmaceuticals Inc   (United States)

^b Quest Pharmaceutical Services   (United States)

Author keywords

autoradiography; cysteine; glutathione; mercapturic acid; Nitroimidazole

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; GLUTATHIONE; MONOGLUTATHIONE; TH 302; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BILE; CELL HYPOXIA; HALF-LIFE; MALE; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

RATTUS;

EID: 84863371486     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.622810     Document Type: Article

References (11)

1. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. (2008). Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 51:2412-2420. (Pubitemid 351628502)
2. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, McKeown SR. (2001). The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 85:625-629. (Pubitemid 32808290)
3. Gibaldi M and Perrier D. (1982). Pharmacokinetics. New York, NY:Marcel Dekker.
4. Hart CP, Ammons S, Duan JX, Jung D, Wang J, Jiao H, Meng F, Lan L, Evans JW, Matteucci M. (2007). Discovery of TH-302: An achiral hypoxia-activated cytotoxic prodrug. J Clin Oncol 25:3515.
5. Hinchman CA, Ballatori N. (1994). Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process. J Toxicol Environ Health 41:387-409. (Pubitemid 24119819)
6. Hinchman CA, Matsumoto H, Simmons TW, Ballatori N. (1991). Intrahepatic conversion of a glutathione conjugate to its mercapturic acid. Metabolism of 1-chloro-2,4-dinitrobenzene in isolated perfused rat and guinea pig livers. J Biol Chem 266: 22179-22185. (Pubitemid 21908632)
7. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR. (2010). A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase IC3, in patients with solid tumors. Cancer Chemother Pharmacol 65:791-801.
8. Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara DR; Southwest oncology group. (2004). Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): A Southwest Oncology Group study. Clin Cancer Res 10:5418-5424. (Pubitemid 39100478)
9. Rischin D, Peters L, Fisher R, Macann A, Denham , Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. (2005). Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in pati nts with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87. (Pubitemid 41702625)
10. Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN. (1999). Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys 44:349-353. (Pubitemid 29205033)
11. Von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. (2000). Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18:1351-1359. (Pubitemid 30159856)